Background: humans after deployment of The paclitaxel-eluting stent (PES) was superior to bare metal stents in the clinical and angiographic outcome of ide-novo and restenotic lesion. Polysulfone polymer PES (PP-PES, Coroflex짰 Please) was coated with same drug (paclitaxel with a dose of 1 關g per mm2 of stent surface) as well as Translute polymer PES (TP-PES, TAXUSTM LibertéTM) stent but had different stent property and polymer. This study was conducted to investigate the comparison of same drug stent with different polymer. Methods : From January 2007 to February 2009, a cohort study of 235 patients has been implanted with PES. (111 patients in PP-PESs, 124 patients in TP-PESs). Primary end point was major adverse cardiovascular event (MACE) at 1 year. MACE was a composite of cardiac death (CD), myocardial infarction (MI) and target vessel revascularization (TVR). Also stent thromboses (ST) by ARC definition were evaluated. Results : All patients were completed follow-up more than 1 year. Baseline demographic and procedural characteristics were similar between PP-PES and TP-PES group. MACE at 1 year were 11.7% ( 3 CD, 3 MI, 7 TVR) in PP-PES group and 9.4% (3 CD, 3 MI, 5 TVR,) in TP-PES group(p=0.429). The stent thrombosis (ST) was 4.5 % (5 patients) in PP-PES group and 2.5% (3 patients) in TP-PES group (p=0.194). Conclusions : PP-PES did not differ from TP-PES in terms of major adverse cardiac events and stent thrombosis during 1 year clinical follow-up. Even though the difference of polymer did not affect the outcome, a large scaled study with long-term clinical and angiographic follow-up will be required.